The efficacy of intravenous immunoglobulin for the treatment of pyoderma gangrenosum: A systematic review and meta‐analysis

医学 坏疽性脓皮病 荟萃分析 皮肤病科 抗体 重症监护医学 免疫学 内科学 疾病
作者
Christian Gan,Dale Jobson,Zhao Feng Liu,Medhir Kumawat,Peter Paul Yu,Shirahn Ballah,Lawrence O. Lin,Hieu Ha,Kevin Vu,Robert Kelly,Christopher Chew
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:39 (3): e273-e275 被引量:1
标识
DOI:10.1111/jdv.20274
摘要

Treatment of pyoderma gangrenosum (PG) is challenging. Research on intravenous immunoglobulin (IVIg) in PG is predominantly case reports; however, studies with larger cohorts have now been published since the last systemic review in 2018.1 We performed a systematic review on patients with pyoderma gangrenosum treated with IVIg using PRISMA guidelines searching MEDLINE, EMBASE and Cochrane databases. Papers were assessed for demographics, treatments, efficacy and adverse effects. Univariable meta-analysis was performed with binary logistic regression using SPSS (Version 28.0, IBM Corp, Armonk, NY, USA). Forty-five papers including 101 patients were identified; an increase from the 2018 systematic review which identified 49 patients.1 PG patient demographics, comorbidities and anatomical sites were similar to other studies on PG populations (Table 1). Notably, our review identified a higher proportion of patients with a haematological disorder than a United Kingdom nation-wide retrospective cohort study (19.0% vs 3.9%).2 >0.999 IVIg was not typically a first-line therapy, with systemic steroids (88.0%), cyclosporine (36.0%), mycophenolate (32.0%), infliximab (20.0%) and adalimumab (20.0%) trialled prior; consistent with the immunosuppressant agents recommended by expert guidelines.3 More patients received biologic therapies prior to IVIg than in the 2018 systematic review; 20% versus 14% trialled infliximab and/or adalimumab prior to IVIg.1 This rise reflects the greater availability of biologics. Most treatments, including biologics, in our review were continued alongside IVIG. IVIg was administered at a median (range) total dose of 2.0 g/kg (0.5–6.0 g/kg) over 4 days (2–7 days), with cycles repeated monthly (median 1, range 0–3 months). A series of 7 patients retained efficacy with a lower dose of 0.5 g/kg/day over 2–3 days—suggesting a lower dose may be effective while reducing the costs of IVIg.4 The number of days IVIg was spread over did not affect treatment outcomes or adverse effects. A response was noted a median of 4 weeks (IQR 1–8) following IVIg commencement. The large IQR of both the time to initial response (1–8 weeks) and treatment length (3–9.1 months) suggests that there is considerable variability between patients. Fifty-seven (57%) cases demonstrated complete or near-complete resolution of PG following IVIg commencement, and 25 (25%) demonstrated partial response (Figure 1). Eighteen (18%) cases reported no response. Four cases employed IVIg monotherapy, of whom all responded (2 partial response and 2 near-complete response).5, 6 Univariate analysis revealed that PG patients undergoing IVIg treatment with previous or concurrent corticosteroid use had a 2.85 (95%CI 1.01–8.08, p-value = 0.049) and 4.41 (95%CI 1.51–12.86, p-value = 0.007) higher odds of achieving partial or complete resolution, respectively. A history of pathergy also demonstrated higher odds of complete resolution (OR3.43, 95%CI 1.21–9.7, p-value = 0.02). In patients with pathergy, the pathogenic mechanisms may be distinct and particularly responsive to IVIg7, 8; however, further research is required. Ten instances of adverse effects were reported of which 3 necessitated treatment cessation—1 case of sepsis and 2 of aseptic meningitis. There were no mortalities attributed to IVIg. Although over half of patients responded well to IVIg, the data are likely impacted by publication bias. Our univariate analysis demonstrating higher odds of resolution with previous or concurrent steroids should be interpreted with caution as most patients (88%) received steroids. The majority of the literature on PG treatments is from low-level evidence, with only two published randomized trials: a trial on infliximab and the STOP GAP trial on prednisolone versus cyclosporine.3, 9 IVIg is effective and safe treatment for PG. It has a role for patients who are poor candidates for immunosuppression, such as patients with malignancies and those at risk of infections.10 The option of a PG treatment that is not immunosuppressive is significant due to its association with malignancies and other autoimmune conditions. No additional acknowledgements. There were no funding sources for this work. The authors declare no conflict of interest. Ethical approval is not required for this systematic review. The data that support the findings of this study are available from the corresponding author upon reasonable request.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
梨涡完成签到 ,获得积分10
1秒前
小二郎的应助被陶醉白梅采纳,获得10
1秒前
金鑫水淼完成签到,获得积分10
1秒前
6666的应助被清脆妙梦采纳,获得40
2秒前
2秒前
风和日丽完成签到,获得积分10
2秒前
搞怪的乐荷完成签到,获得积分10
2秒前
2秒前
颜紫萱发布了新的文献求助10
3秒前
molihuakai的应助被8mian采纳,获得10
3秒前
匿名用户完成签到,获得积分10
3秒前
3秒前
荒1完成签到,获得积分10
4秒前
5秒前
6秒前
6秒前
8秒前
JamesPei的应助被十三月的萧邦采纳,获得10
8秒前
8秒前
深情安青的应助被小刘接好运采纳,获得10
8秒前
cchh完成签到,获得积分10
8秒前
蓝胖子完成签到 ,获得积分10
8秒前
酷波er的应助被8mian采纳,获得10
9秒前
9秒前
9秒前
马巧巧发布了新的文献求助30
9秒前
哈哈完成签到,获得积分20
9秒前
大模型的应助被Anben采纳,获得10
10秒前
852的应助被cwlm12采纳,获得10
10秒前
科研人完成签到 ,获得积分10
10秒前
蕾先生发布了新的文献求助10
10秒前
10秒前
10秒前
木木彡发布了新的文献求助10
12秒前
Maestro_S的应助被吱吱采纳,获得10
12秒前
業業发布了新的文献求助10
13秒前
偷猪雅贼完成签到,获得积分10
13秒前
zz完成签到 ,获得积分10
14秒前
14秒前
英俊的铭的应助被从容的半蕾采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188118
求助须知:如何正确求助?哪些是违规求助? 9575977
关于积分的说明 21844428
捐赠科研通 7785918
什么是DOI,文献DOI怎么找? 3435205
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482065